| Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Calculator-free point-of-care prognostication in myelodysplastic syndromes. |
|
Am J Hematol |
Myelodysplastic Syndromes (MDS) |
| Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes |
|
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
| Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria |
|
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Characterization of Myelodysplastic Syndromes (MDS) With T-cell Large Granular Lymphocyte Proliferations (LGL) |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
